Effect of Alteplase Use on Outcomes in Patients With Atrial Fibrillation: Analysis of the Initiation of Anticoagulation After Cardioembolic Stroke Study.

Journal Article (Journal Article)

Background Intravenous alteplase improves outcome after acute ischemic stroke without a benefit in 90-day mortality. There are limited data on whether alteplase is associated with reduced mortality in patients with atrial fibrillation (AF)-related ischemic stroke whose mortality rate is relatively high. We sought to determine the association of alteplase with hemorrhagic transformation and mortality in patients with AF. Methods and Results We retrospectively analyzed consecutive patients with acute ischemic stroke between 2015 and 2018 diagnosed with AF included in the IAC (Initiation of Anticoagulation After Cardioembolic Stroke) study, which pooled data from stroke registries at 8 comprehensive stroke centers across the United States. For our primary analysis, we included patients who did not undergo mechanical thrombectomy (MT), and secondary analyses included patients who underwent MT. We used binary logistic regression to determine whether alteplase use was associated with risk of hemorrhagic transformation and 90-day mortality. There were 1889 patients (90.6%) who had 90-day follow-up data available for analyses and were included; 1367 patients (72.4%) did not receive MT, and 522 patients (27.6%) received MT. In our primary analyses we found that alteplase use was independently associated with an increased risk for hemorrhagic transformation (odds ratio [OR], 2.23; 95% CI, 1.57-3.17) but reduced risk of 90-day mortality (OR, 0.58; 95% CI, 0.39-0.87). Among patients undergoing MT, alteplase use was not associated with a significant reduction in 90-day mortality (OR, 0.68; 95% CI, 0.45-1.04). Conclusions Alteplase reduced 90-day mortality of patients with acute ischemic stroke with AF not undergoing MT. Further study is required to assess the efficacy of alteplase in patients with AF undergoing MT.

Full Text

Duke Authors

Cited Authors

  • Yaghi, S; Mistry, E; de Havenon, A; Leon Guerrero, CR; Nouh, A; Liberman, AL; Giles, J; Liu, A; Nagy, M; Kaushal, A; Azher, I; Mac Grory, B; Fakhri, H; Brown Espaillat, K; Asad, SD; Pasupuleti, H; Martin, H; Tan, J; Veerasamy, M; Esenwa, C; Cheng, N; Moncrieffe, K; Moeini-Naghani, I; Siddu, M; Scher, E; Trivedi, T; Wu, T; Khan, M; Keyrouz, S; Furie, K; Henninger, N

Published Date

  • August 3, 2021

Published In

Volume / Issue

  • 10 / 15

Start / End Page

  • e020945 -

PubMed ID

  • 34323120

Pubmed Central ID

  • PMC8475683

Electronic International Standard Serial Number (EISSN)

  • 2047-9980

Digital Object Identifier (DOI)

  • 10.1161/JAHA.121.020945


  • eng

Conference Location

  • England